In conclusion, our study explored the challenging landscape of the KRAS gene, emphasizing its intricate network and molecular heterogeneity across colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) patients. This evidence concerns the gene KRAS and colorectal carcinoma.